Negotiating prices of drugs for rare diseases

Bulletin of the World Health Organization

Volumn 94, Issue 10, 2016, Pages 779-781

  Henrard, Séverine ^a   Arickx, Francis ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b National Institute for Health and Disability Insurance   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

COMMODITY MARKET; DIABETES; DISEASE TREATMENT; DRUG DEVELOPMENT; EUROPEAN UNION; HEALTH SERVICES; NEGOTIATION PROCESS; PRICING POLICY; WORLD HEALTH ORGANIZATION;

ARTICLE; CLINICAL FEATURE; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; EUROPEAN MEDICINES AGENCY; HEALTH CARE SYSTEM; NONHUMAN; PREVALENCE; RARE DISEASE;

EUROPE; UNITED STATES;

EID: 84989315112     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.15.163519     Document Type: Article

References (14)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council 8. of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. 2000;L018(43):1-6.
2. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official J Eur Union. 2009 Jul 9. 3;52:7-10. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2009:151:TOC [cited 2016 Aug 16].
3. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 10. 2035. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49. doi: http://dx.doi.org/10.1016/j.diabres.2013.11.002 PMID: 24630390
4. Graf von der Schulenburg JM, Frank M. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. Eur J Health 11. Econ. 2015 Mar;16(2):113-8. doi: http://dx.doi.org/10.1007/s10198-014-0639-8 PMID: 25355295
5. Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, et al. Rare 12. diseases and effective treatments: are we delivering? Lancet. 2015 Feb 28;385(9970):750-2. doi: http://dx.doi.org/10.1016/S0140-6736(15)60297-5 PMID: 25752159 13.
6. Orphanet report series. Lists of medicinal products for rare diseases in Europe. January 2016 [Internet]. Paris: Orphanet; 2016. Available from http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf [cited 2015 Apr 5]. 14.
7. Henrard S, Hermans C. Rare diseases and orphan drugs in Belgium and in the European Union: what is the current situation? Louv Med. 2015 Dec;134(10):527-34. French.
8. Henrard S, Devleesschauwer B, Beutels P, Callens M, De Smet F, Hermans C, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis. 2014 03 21;9(1):39. doi: http://dx.doi.org/10.1186/1750-1172-9-39 PMID: 24655371
9. Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011 Jul 1;9(4):275-9. doi: http://dx.doi.org/10.2165/11590170-000000000-00000 PMID: 21682354
10. Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis. 2014 10 11;9(1):154. doi: http://dx.doi.org/10.1186/s13023-014-0154-0 PMID: 25304026
11. Picavet E, Cassiman D, Simoens S. Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis. 2014 09 12;9(1):139. doi: http://dx.doi.org/10.1186/s13023-014-0139-z PMID: 25208770
12. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011 06 17;6(1):42. doi: http://dx.doi.org/10.1186/1750-1172-6-42 PMID: 21682893
13. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295-301. doi: http://dx.doi.org/10.3111/13696998.2010.491427 PMID: 20482245
14. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: World Health Organization Regional Office for Europe; 2015. Available from: http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf [cited 2016 Jul 20].